Ontario Bioscience Industry Organization » healthcare http://obio.ca Ontario's leading advocate for the life sciences sector Tue, 31 Jan 2012 19:15:25 +0000 http://wordpress.org/?v=2.9.1 en hourly 1 Q1 2010 Canadian Healthcare Review http://obio.ca/2010/04/q1-2010-canadian-healthcare-review/ http://obio.ca/2010/04/q1-2010-canadian-healthcare-review/#comments Wed, 28 Apr 2010 11:20:03 +0000 obio http://obio.ca/?p=297 Financing
Public Canadian healthcare companies completed equity and convertible debt financings during this quarter for total gross proceeds of $236.0 million (Appendix 1). The largest financing in the sector was the only financing in the Services group, $86.3 million by Extendicare. The largest financing in the Therapeutics group was $34.5 million from a rights offering by Wex Pharmaceuticals, with 97.6% of the shares being issued to its largest shareholder. Excluding these two financings, the rest of the sector raised $115.2 million. Other financing vehicles also provided some current and future funds for companies. Merck advanced US$25 million to Cardiome under a secured, interest-bearing credit facility which is a component of their partnership for vernakalant. Allon Therapeutics and Resverlogix established Standby Equity Distribution Agreements (SEDAs) for $10 million and $25 million, respectively, but have not yet made any draw downs under these agreements. Bioniche Life Sciences received US$8 million in milestone payments under its partnership with Endo.

Click here to read the entire review

]]> http://obio.ca/2010/04/q1-2010-canadian-healthcare-review/feed/ 0